Navigation Links
Cell Therapeutics Announces Closing of Sale of Convertible Preferred Stock
Date:9/18/2013

SEATTLE, Sept. 19, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced the closing of its previously announced sale of 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent for gross proceeds of approximately $15 million (the "Offering").  On September 18, 2013, all of the shares of Series 18 Preferred Stock were converted and investors received 15,000,000 shares of common stock issuable upon conversion. The net proceeds from the Offering, after deducting estimated offering expenses, were approximately $14.8 million.

CTI plans to use the net proceeds from the Offering to continue Phase 3 trials of pacritinib and to support the commercialization of PIXUVRI® (pixantrone) in Europe as well as for general corporate purposes, which may include, among other things, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications and general working capital. 

The securities described above were offered by CTI pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"), which the SEC declared effective on November 1, 2011.  A prospectus supplement related to the Offering was filed with the SEC and is available on the SEC's website located at http://www.sec.gov

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. 
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
2. Cell Therapeutics Announces Sale of Convertible Preferred Stock
3. BGI Tech and South Texas Accelerated Research Therapeutics Initiate Collaboration to Advance Unique San Antonio 1000 Cancer Genome Project
4. Breckenridge Completes Acquisition of Certain Cypress Products from Pernix Therapeutics
5. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
6. Sorrento Therapeutics Completes IgDraSol Merger
7. MicroConstants China In-licenses Phase 2 Liver Cancer Drug from Canadian Pertinax Therapeutics
8. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
9. Sorrento Therapeutics to Present at Two Healthcare Conferences
10. Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013
11. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... und MARSEILLE , Frankreich, ... , Weltweite Exklusivlizenz der Universität ... die Entwicklung von Tests auf SF3B1-Mutationen, einschließlich ... Neuer Test weist Mutationen des SF3B1-Gens ... Syndromen) einen günstigen Krankheitsverlauf vermuten lassen  ...
(Date:7/24/2014)... Inc. (NasdaqGS: ABAX ), a medical products ... results for the first fiscal quarter ended June 30, ... of $47.5 million, up 10% over last year,s comparable ... over last year,s comparable quarter. Revenues highlights: ... 20% over last year,s comparable quarter. , Veterinary ...
(Date:7/24/2014)... OAKS, Calif. , July 24, 2014 Amgen ... report its second quarter financial results on Tuesday, July 29, ... announcement will be followed by a conference call with the ... from Amgen will be Robert A. Bradway , chairman ... management team. Live audio of the conference call ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
(Date:7/27/2014)... analysis of hepatitis E virus (HEV) transmission by blood ... England have HEV in their plasma. The findings, published ... HEV-containing blood components (eg, red cells, platelets, and fresh ... in England. , The study retrospectively screened 225 ... between Oct, 2012 and Sept, 2013 for HEV RNA. ...
(Date:7/27/2014)... The report, “Glass Fiber & Glass Fiber Reinforced ... Manufacturing Process, By Application (Transportation, Construction, Electrical & ... Trends & Forecast to 2019”, defines and segments ... and forecast by value and volume. , Browse ... through 347 slides and in-depth TOC on "GFRP ...
(Date:7/27/2014)... Manchester have discovered why medication to treat asthma and pneumonia ... Medicine , show that drugs widely used to treat lung ... the UK pneumonia, which is caused by an infection, affects ... serious for babies, young children, the elderly, smokers and those ... million people in the UK are affected by asthma and ...
(Date:7/27/2014)... Over the past five years, the ... thanks to many consumers valuing the taste and versatility ... Association of Canada's Canadian Coffee Drinking Study in 2011 ... per day. “This trend, coupled with many studies that ... tea on a daily basis, has stimulated consumer demand ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel Filter Market by ... (OE & Aftermarket), Filter Type (Oil & Fuel), Fuel ... & Forecast to 2018”, defines and segments the global ... forecasting of the global volume and revenue. The market ... revenue of $6.1 billion in 2018, while fuel filter ...
Breaking Medicine News(10 mins):Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Drugs used to treat lung disease work with the body clock 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5
... TUCSON, Ariz., Nov. 25 ... announced that its LogistiCare subsidiary, the nation,s largest coordinator ... award from the State of Florida Commission for the ... both Miami-Dade and Volusia Counties. The award, estimated ...
... , - Agreement Provides Financial Flexibility, Allowing ... Quebec, Nov. 25 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: ... standby equity distribution agreement (SEDA) with YA Global Master SPV ... terms of the agreement, YA has committed to provide up ...
... and other greenhouse emissions will have major direct health ... change, especially in low-income countries, according to a series ... the British journal The Lancet . Two ... Kirk R. Smith, professor of global environmental health, and ...
... ... sinusitis. A clinically proven, minimally invasive technology for treating chronic sinus inflammation is available ... a small catheter and balloon to quickly open and expand blocked sinuses. , ... (Vocus) November 25, 2009 ...
... ... be offering $100 off every memory foam and latex sofa bed mattress + an additional ... code “BLACKFRIDAY” in the shopping cart to take advantage of this special offer. , ... (PRWEB) November 25, 2009 -- Millions ...
... ... your Emergency Department,s management of seasonal and pandemic novel H1N1 influenza cases this season? ... Which - if any - antiviral should you prescribe? EB Medicine announces its November ... resources on influenza diagnosis and treatment. , ...
Cached Medicine News:Health News:Providence Service Corporation's LogistiCare Subsidiary Announces Non-Emergency Medical Transportation Contracts Worth Over $11 Million Annually in Florida 2Health News:Providence Service Corporation's LogistiCare Subsidiary Announces Non-Emergency Medical Transportation Contracts Worth Over $11 Million Annually in Florida 3Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 2Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 3Health News:Cutting greenhouse pollutants could directly save millions of lives worldwide 2Health News:Cutting greenhouse pollutants could directly save millions of lives worldwide 3Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 2Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 3Health News:Providing Comfort for Holiday Guests Just Got Easier 2Health News:Providing Comfort for Holiday Guests Just Got Easier 3Health News:Emergency Medicine Practice Publishes 'Influenza: Challenges in Diagnosis and Management in the Emergency Department' 2Health News:Emergency Medicine Practice Publishes 'Influenza: Challenges in Diagnosis and Management in the Emergency Department' 3
... first manufacturer to offer through-the-lens (TTL) ... These next generation loupes feature extremely ... design, and are multi-coated lens for ... SheerVision's proprietary SureFit system - you ...
Easy pull-on garment's feature Rainey's exclusive Non-Slip Dome™design and adjustable Velcro© closure at neck for optimal comfort and support. Choose covered or non covered ear design....
Facial Wrap...
CDIs Chin Support Bandage is ideal for Submental Liposuction, Chin Implants and all other facial procedures requiring support. Adjustable Velcro® top and posterior band secures placement....
Medicine Products: